Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
Cat.No. : CSC-RR0468 Host Cell: OVCAR8
| Cat. No. | CSC-RR0468 |
| Description | This cell line is engineered to stably overexpress GFP reporter gene. OVCAR8 cell line is a human ovarian carcinoma cell line that has been widely used in laboratory research. This cell line is a useful tool for fluorescent tracking of OVCAR8 cells. |
| Gene | GFP |
| Host Cell | OVCAR8 |
| Host Cell Species | Homo sapiens (Human) |
| Stability | Validated for at least 10 passages |
| Reporter Type | Fluorescent protein |
| Application | 1. Gene expression studies 2. Protein localization 3. Drug screening and toxicology 4. Live cell imaging |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
The researchers investigated the role of NUAK1, a key substrate of the master kinase LKB1, in epithelial ovarian cancer (EOC) metastasis. They found that LKB1 is crucial for NUAK1 phosphorylation and stability. Ectopic expression of NUAK1 in EOC cells enhanced adhesion and spheroid integrity, while NUAK1 knockout (KO) led to weakened spheroid formation and increased cell death. Transcriptome analysis revealed reduced expression of cell interaction pathways and fibronectin in NUAK1 KO spheroids. Supplementing with soluble fibronectin restored spheroid integrity. In a xenograft model, NUAK1 loss extended survival and decreased fibronectin levels in tumors. This study highlights a novel mechanism where LKB1-NUAK1 signaling supports EOC metastasis through fibronectin-mediated spheroid formation.
Figure 1. The researchers found that OVCAR8 cells with NUAK1 knockout formed less compact spheroids compared to control cells. The GFP stable cell line OVCAR8-GFP showed intact spheroids, while the OVCAR8-NUAK1KO-GFP spheroids displayed poor integrity and increased cell detachment, indicating that NUAK1 is essential for maintaining spheroid structure and cell adhesion. (Fritz JL, et al., 2020)
Creative Biogene's GFP Stable Cell Line - OVCAR8 is ideal for studying EOC metastasis. It allows real-time tracking of cell behavior and spheroid formation, making it perfect for exploring the effects of gene modifications on cancer dynamics. Its high fluorescence sensitivity enhances research accuracy and insights.
A: The GFP Stable Cell Line - OVCAR8 enables researchers to visualize various cellular processes such as gene expression, protein localization, and cellular trafficking in real-time. By observing these processes in a cell line that models ovarian cancer, researchers can gain insights into the mechanisms that drive cancer progression. For instance, tracking the movement of key proteins involved in cell division or migration can reveal how these processes are altered in cancer cells, potentially leading to the identification of novel therapeutic targets.
A: The OVCAR8 cell line expressing GFP can be genetically modified to either overexpress or silence specific genes of interest to assess their role in ovarian cancer biology. By comparing the effects of these genetic modifications on GFP expression levels or cellular behavior, researchers can determine the impact of these genes on cancer progression and treatment response. This approach is particularly useful for validating potential therapeutic targets and for optimizing gene therapy strategies.
A: When using the GFP Stable Cell Line - OVCAR8 to study the response to chemotherapy, it is important to consider the timing and dosage of drug exposure. Researchers must ensure that the GFP fluorescence is not affected by the drugs, which could interfere with the data interpretation. Additionally, it is crucial to monitor the cells over an appropriate time frame to capture the full response to the treatment, including any potential recovery or resistance mechanisms that may develop.
A: The GFP Stable Cell Line - OVCAR8 can be co-cultured with other cell types that represent components of the tumor microenvironment, such as immune cells or stromal cells. By observing changes in GFP fluorescence and cellular behavior in response to these interactions, researchers can investigate how the microenvironment influences cancer cell survival, invasion, and drug resistance. This can provide valuable insights into the complex interplay between cancer cells and their surroundings.
A: The GFP Stable Cell Line - OVCAR8 can be used to dissect the signaling pathways that are critical for ovarian cancer cell survival and proliferation. By manipulating these pathways through the use of specific inhibitors or activators and monitoring the effects on GFP expression and cell behavior, researchers can identify key nodes that are susceptible to targeted therapies. This approach can facilitate the development of more effective, personalized treatment strategies for ovarian cancer patients.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Tailored for ovarian cancer studies, the GFP Stable Cell Line - OVCAR8 provides a relevant model for investigating ovarian cell biology and oncogenic processes, facilitating targeted research and potential therapeutic development.
Germany
06/19/2022
With stable GFP integration, the GFP Stable Cell Line - OVCAR8 ensures consistent fluorescence across passages, enhancing the reliability of long-term experiments and reducing variability in results.
United Kingdom
01/22/2024
GFP allows for enhanced visualization of OVCAR8 cells, aiding in the monitoring of cell morphology, proliferation, and migration, which are critical aspects of cancer research.
Germany
06/25/2023
The GFP expression in the GFP Stable Cell Line - OVCAR8 can be used to assess transfection efficiency rapidly, which is essential for gene editing experiments and studies involving the introduction of new genetic material.
Canada
12/02/2023
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.